Polivy

(Polatuzumab Vedotin)

Phase 3Antibody–drug conjugate

Polatuzumab vedotin is used to treat certain types of blood cancers, specifically a form of lymphoma called diffuse large B-cell lymphoma, usually in combination with other chemotherapy drugs.[1] Polivy is currently being investigated across 14 indications[3], with its most advanced program in Phase 3.[1]

Polivy is one of 223 small molecule programs targeting Non-Hodgkins Lymphoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

222

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Non-Hodgkins LymphomaActive, not recruiting

B-Cell NeoplasmUnknown

LymphomaActive, not recruiting

B-Cell Non-Hodgkins LymphomaUnknown

Mantle Cell LymphomaActive, not recruiting

Diffuse Large B-Cell LymphomaUnknown

Chronic Lymphocytic LeukemiaActive, not recruiting

Non-Hodgkin LymphomaActive, not recruiting

Large B-Cell LymphomaNot yet recruiting

Lymphoma, Large B-Cell, DiffuseRecruiting

Non-Hodgkins LymphomaPhase 3

Active, not recruiting

B-Cell NeoplasmPreclinical

Unknown

LymphomaPhase 1

Active, not recruiting

B-Cell Non-Hodgkins LymphomaPreclinical

Unknown

Mantle Cell LymphomaPhase 2

Active, not recruiting

Diffuse Large B-Cell LymphomaPreclinical

Unknown

Chronic Lymphocytic LeukemiaPhase 1

Active, not recruiting

Non-Hodgkin LymphomaPhase 2

Active, not recruiting

Large B-Cell LymphomaPreclinical

Not yet recruiting

Lymphoma, Large B-Cell, DiffusePhase 2

Recruiting

Showing 10 of 14 indications

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Polivy

Roche

Phase 3

18 2

Velban

EEastern Cooperative Oncology Group

Preclinical

15 3

Zofran

Novartis

Preclinical

2 4

Tafasitamab

Incyte

Preclinical

7 5

Nuvigil

NNuvo Research GmbH

Preclinical

1 6

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—7

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—8

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

—9

Rhg-CSF

CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Preclinical

3 10

Stem Cells

KKang Stem Biotech Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Active, not recruiting

Lymphoma

NCT04479267

Phase 2Active, not recruiting

Older Patients

NCT04594798

Phase 2Not yet recruiting

First-Line

NCT07012980

Phase 2Recruiting

Treatment

NCT06530511

Q4 2026

PreclinicalActive, not recruiting

Non-Hodgkins Lymphoma

NCT03533283

Phase 2Active, not recruiting

Diffuse Large B-Cell Lymphoma

NCT05498220

Clinical

Trials by Indication[1]

Diffuse Large B-Cell Lymphoma20 trials

Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Active, not recruiting·—·Phase 2·NCT04665765·41 enrolled

Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma

Active, not recruiting·MMayo Clinic·Phase 1·NCT04323956·50 enrolled

A Study of Zanubrutinib in Combination With Polatuzumab Vedotin, Bendamustine and Rituximab in the Treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma

Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT06554600·36 enrolled

Show 17 more trials

A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Completed· Roche logo

Roche·Phase 1/2·NCT02600897·114 enrolled

Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma

Not yet recruiting·MMedical College of Wisconsin·Phase 2·NCT06594939·31 enrolled

A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma

Active, not recruiting· Roche logo

Roche·Phase 3·NCT03274492·1,000 enrolled

Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Recruiting·SSWOG Cancer Research Network·Phase 2·NCT05633615·396 enrolled

Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)

Withdrawn·KKaryopharm Therapeutics Inc·Phase 1/2·NCT04607772

Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL)

Active, not recruiting·GGWT-TUD GmbH·Phase 3·NCT04833114·306 enrolled

A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma

Completed· Roche logo

Roche·Phase 1/2·NCT02257567·331 enrolled

A Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination With Bendamustine and Rituximab Compared With Bendamustine and Rituximab Alone in Chinese Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL).

Terminated· Roche logo

Roche·Phase 3·NCT04236141·42 enrolled

A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Completed· Roche logo

Roche·Phase 3·NCT04182204·270 enrolled

Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma

Completed· Roche logo

Roche·Phase 1/2·NCT03677154·188 enrolled

A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)

Completed· Roche logo

Roche·Phase 1/2·NCT02611323·133 enrolled

A Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Completed· Roche logo

Roche·Phase 1/2·NCT02729896·36 enrolled

A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL)

Terminated· Roche logo

Roche·Phase 1·NCT04790903·50 enrolled

Pirtobrutinib in Combination With Rituximab, Gemcitabine, Oxaliplatin With or Without Polatuzumab Vedotin in Covalent BTK Inhibitor-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Not yet recruiting·RRuijin Hospital·Phase 2·NCT07122609·22 enrolled

Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma

Active, not recruiting·UUNC Lineberger Comprehensive Cancer Center·Phase 2·NCT05498220·5 enrolled

The Effectiveness and Safety of Polatuzumab in Real-World Clinical Practice Among Chinese Adult Patients With Diffuse Large B-Cell Lymphoma: A Prospective, Observational, Multicenter, Registry Study

Recruiting· Roche logo

Roche··NCT05954910·1,000 enrolled

Immunostart: Prephase Tafasitamab, Retifanlimab, and Rituximab (TRR), Followed by TRR With Standard Therapy for Previously Untreated Diffuse Large B-Cell Lymphoma

Active, not recruiting·UUniversity of Washington·Preclinical·NCT05455697·33 enrolled

Lymphoma18 trials

A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL)

Active, not recruiting·PPeter MacCallum Cancer Centre, Australia·Phase 1/2·NCT04914741·80 enrolled

A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)

Recruiting·AADC Therapeutics S.A.·Phase 1·NCT04970901·200 enrolled

A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma

Completed· Roche logo

Roche·Phase 1/2·NCT01992653·85 enrolled

Show 15 more trials

Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma

Completed·UUniversity of Washington·Phase 2·NCT05169658·42 enrolled

A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma

Active, not recruiting· Roche logo

Roche·Phase 1/2·NCT03671018·422 enrolled

A Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab As a Peri-CAR-T Cell Treatment Strategy in Large B-cell Lymphoma

Recruiting·UUniversity College, London·Phase 2·NCT06071871·99 enrolled

Zanubrutinib in Combination With Pola-R-CHP and High-dose Methotrexate in Patients With Secondary CNS Lymphoma

Recruiting·—·Phase 1·NCT06730542·20 enrolled

Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma

Recruiting·UUniversity of Washington·Phase 1·NCT04231877·56 enrolled

Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma

Active, not recruiting·BBarbara Ann Karmanos Cancer Institute·Phase 2·NCT04479267·8 enrolled

Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma

Unknown status·NNew York Medical College·Phase 1/2·NCT04491370·20 enrolled

Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP

Active, not recruiting·IInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest·Phase 2·NCT05798156·125 enrolled

Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma

Withdrawn· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT04882163

An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma

Active, not recruiting· Roche logo

Roche·Phase 3·NCT06047080·1,130 enrolled

Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma

Recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT04884035·174 enrolled

A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

Active, not recruiting· Roche logo

Roche·Phase 3·NCT05171647·208 enrolled

A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

Completed· Roche logo

Roche·Phase 1/2·NCT01691898·231 enrolled

A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL

Completed· Roche logo

Roche·Phase 1·NCT03467373·111 enrolled

A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma

Completed· Roche logo

Roche·Phase 1/2·NCT03677141·117 enrolled

Richter's Transformation2 trials

Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation

Recruiting·WWeill Medical College of Cornell University·Phase 2·NCT04679012·20 enrolled

Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation

Recruiting·CChristine Ryan·Phase 2·NCT06043674·70 enrolled

Efficacy and Safety2 trials

A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL

Not yet recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT06516978·528 enrolled

Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL

Recruiting·RRuijin Hospital·Phase 2·NCT06803693·152 enrolled

Mantle Cell Lymphoma2 trials

Study of PV in Combination With Bendamustine and Rituximab for Patients With R/R MCL

Not yet recruiting·CCzech Lymphoma Study Group·Phase 2·NCT04913103·21 enrolled

Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Terminated·—·Phase 2·NCT04659044·3 enrolled

18 more indications

Follicular Lymphoma2 trials

Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma

Active, not recruiting·WWashington University School of Medicine·Phase 2·NCT05410418·34 enrolled

Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma

Recruiting·—·Phase 2·NCT06453044·41 enrolled

Elderly Patients2 trials

CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL

Recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT07397832·58 enrolled

Phase Ib/II Study of Polatuzumab Vedotin in Combination With Rituximab and Chidamide in Newly Diagnosed Elderly Patients With Double-Expressor DLBCL

Not yet recruiting·SSun Yat-sen University·Phase 1/2·NCT07415980·68 enrolled

B-cell non-Hodgkins lymphoma1 trial

A Study of Escalating Doses of Polatuzumab Vedotin in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia and Polatuzumab Vedotin in Combination With Rituximab in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma

Completed· Roche logo

Roche·Phase 1·NCT01290549·95 enrolled

Older Patients1 trial

A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL

Active, not recruiting·UUniversity of Rochester·Phase 2·NCT04594798·39 enrolled

Newly Diagnosed1 trial

Polatuzumab Vedotin and Zanubrutinib Plus R-CHP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL

Enrolling by invitation·TThe First Affiliated Hospital of Soochow University·Phase 2·NCT06468943·20 enrolled

Treatment1 trial

Polatuzumab, Rituximab and Orelabrutinib Combination Regimen (PRO) in the Treatment of Elderly Frail Patients with Treatment-naive Non-GCB DLBCL

Recruiting·—·Phase 2·NCT06530511·30 enrolled

Efficacy1 trial

Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL

Not yet recruiting·RRuijin Hospital·Phase 2·NCT06441097·152 enrolled

Relapsed or Refractory1 trial

POLA+BR for Relapsed or Refractory DLBCL

Withdrawn·UUniversity of Colorado, Denver·Phase 2·NCT04535102

Lenalidomide1 trial

A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT05615636·36 enrolled

First-line1 trial

Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL

Not yet recruiting·SShanghai Zhongshan Hospital·Phase 2·NCT07012980·38 enrolled

Phase II1 trial

A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1

Not yet recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT07034508·134 enrolled

Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue1 trial

MOZART MZL: A Randomized Phase II Study Evaluating Mosunetuzumab Alone and in Combination With Either Zanubrutinib or Polatuzumab Vedotin for the Treatment of Patients With Relapsed/Refractory Marginal Zone Lymphoma

Not yet recruiting·SSWOG Cancer Research Network·Phase 2·NCT07638722·138 enrolled

Lymphoma, Large B-Cell, Diffuse1 trial

A Randomized, Open-label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) Plus R-CHP Versus Polatuzumab Vedotin Plus R-CHP in Treatment-naïve Participants With GCB Subtype of Diffuse Large B-cell Lymphoma (DLBCL)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 2·NCT06890884·594 enrolled

Diffuse Large B-Cell Lymphoma, Not Otherwise Specified1 trial

A Phase 1 Study of Mosunetuzumab With Polatuzumab Vedotin and Lenalidomide (M+Pola+Len) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT06015880·30 enrolled

Non-Hodgkin Lymphoma1 trial

Phase 1b/2, Open-Label Study to Evaluate Safety and Tolerability of Epcoritamab in Combination With Anti-Neoplastic Agents in Subjects With Non-Hodgkin Lymphoma

Active, not recruiting· Genmab logo

Genmab·Phase 2·NCT05283720·264 enrolled

Non-Hodgkins Lymphoma1 trial

An Open-Label, Multi-Center, Phase IB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin (Plus a Single Pre-Treatment Dose of Obinutuzumab) in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Active, not recruiting· Roche logo

Roche·Preclinical·NCT03533283·211 enrolled

Post-Transplant Lymphoproliferative Disorder1 trial

A Phase I/II Study of Frontline Therapy With Polatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative Disorder (PTLD)

Active, not recruiting·WWashington University School of Medicine·Preclinical·NCT06040320·12 enrolled

Large B-cell Lymphoma1 trial

A Single-Arm, Prospective Study of Pola-R-CHP Plus Sonrotoclax in Patients With Previously Untreated Large B-Cell Lymphoma (LBCL) With High BCL2 Expression / Double-Hit Lymphoma

Not yet recruiting·RRuijin Hospital·Preclinical·NCT07638787·40 enrolled

Regulatory

FDA Approval Timeline[4]

Jun 10, 2019

POLIVY

BLA BLA761121

Sources

References

[1]
ClinicalTrials.gov — 64 trial records for Polatuzumab Vedotin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Polatuzumab Vedotin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Polatuzumab Vedotin. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (BLA BLA761121). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Tubulin Inhibitor; B-Cell Antigen Receptor Complex-Associated Protein Beta Chain Binding Agent[2]
Modality: Antibody–drug conjugate[2]
Highest Phase: Phase 3[1]
Company: Roche

Polivy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2026

Trials by Indication[1]

Diffuse Large B-Cell Lymphoma20 trials

Lymphoma18 trials

Richter's Transformation2 trials

Efficacy and Safety2 trials

Mantle Cell Lymphoma2 trials

Follicular Lymphoma2 trials

Elderly Patients2 trials

B-cell non-Hodgkins lymphoma1 trial

Older Patients1 trial

Newly Diagnosed1 trial

Treatment1 trial

Efficacy1 trial

Relapsed or Refractory1 trial

Lenalidomide1 trial

First-line1 trial

Phase II1 trial

Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue1 trial

Lymphoma, Large B-Cell, Diffuse1 trial

Diffuse Large B-Cell Lymphoma, Not Otherwise Specified1 trial

Non-Hodgkin Lymphoma1 trial

Non-Hodgkins Lymphoma1 trial

Post-Transplant Lymphoproliferative Disorder1 trial

Large B-cell Lymphoma1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News